IGC Pharma reports 9-month revenue $969K

Reports 9-month net loss ($4.1M) vs. ($5.9M) a year ago. “We have surpassed 70% enrollment in the Phase 2 CALMA clinical trial, marking a significant acceleration as the program advances toward key development milestones,” said Ram Mukunda, CEO of IGC Pharma (IGC). “CALMA is evaluating our lead candidate, IGC-AD1, for agitation in Alzheimer’s dementia, a critical area of unmet medical need with a massive global footprint. As we move toward full enrollment and a defined clinical readout, our focus remains on disciplined execution and the creation of long-term value for our patients and shareholders.”